Eliezer Van Allen

Eliezer Van Allen is a computational oncologist who has made landmark contributions to understanding the genomic determinants of immunotherapy response and immune evasion. He performed the first comprehensive whole exome sequencing of anti-CTLA-4 immunotherapy responders versus non-responders in melanoma, identifying mutational load as a determinant of clinical benefit and providing the conceptual basis for TMB as a pan-tumor immunotherapy biomarker. Van Allen has characterized genomic features associated with immune escape including antigen presentation pathway mutations, and has developed machine learning approaches to predict immunotherapy response from tumor genomic profiles.